Biologically Active Substance – Page 45

Akero Reinforces Phase III FGF21 Analog Candidate with Enhanced Fibrosis Response Rates in MASH Data Update

2 years ago talkbio0Tagged Analog, Antibody-Drug, Efruxifermin, fibroblast growth factor 21, Fibrosis Response Rate, Improvements, metabolic dysfunction-associated steatohepatitis, Phase IIb HARMONY Study, Statistical Significance

Akero Therapeutics, FGF21 Analog, efruxifermin (EFX), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Phase IIb HARMONY Study, Fibrosis Response Rate, 96 Weeks, Statistically Significant Improvements

Jazz Pharmaceuticals Expands Oncology Pipeline with Redx’s KRAS Inhibitor Program

2 years ago talkbio0Tagged Inhibitor, Jazz, Kirsten murine sarcoma virus, Redx

Kirsten murine sarcoma virus, Jazz, Redx, Inhibitor

AbbVie pours $223M into building out its biologics capacity in Singapore

2 years ago talkbio0Tagged AbbVie, Biological Factors, Capacity, expansion, Investments, Manufacture, Singapore

Biological Factors, expansion, AbbVie, Capacity, Investments, Manufacture, Singapore